- Also, positive top-line results released Wednesday from a phase 3 head-to-head trial indicating Brukinsa bested Imbruvica in terms of better progression-free survival in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma patients bodes well.
- Beigene has also benefitted from a National Comprehensive Cancer Network decision in August to include Brukinsa as a Category 1 recommendation for CLL.
- Schmidt added that while the company's stock price is down ~70% over the last year, it doesn't account for the potential of BeiGene's ( BGNE ) product portfolio and pipeline.
- Check out Seeking Alpha contributor William Meyers' assessment of BeiGene ( BGNE ).
For further details see:
BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential